Announcements Trials
Browse Landscape

Status

Completed 5Withdrawn 1

Sponsor Class

INDUSTRY 6

Study Type

Observational 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 43Prostatic Neoplasms, Castration-Resistant 6Neoplasm Metastasis 5Metastatic Castration-resistant Prostate Cancer 4Breast Neoplasms 4Prostate Carcinoma Metastatic to the Bone 2Neoplasms 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Hormone Refractory Prostate Cancer 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bone Metastatic Castration-resistant Prostate Cancer 2Thyroid Neoplasms 1Prostate Cancer Metastatic to Bone 1Prostate Adenocarcinoma 1Pain 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Lymphatic Metastasis 1Lung Neoplasms 1Fractures, Bone 1Fatigue 1Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Bony Metastases From Castrate Refractory Prostate Cancer 1Bone Neoplasms 1Bone Metastases 1Bone Diseases 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

enzalutamide 20Abiraterone Acetate 11Prednisone 7Docetaxel 7radium Ra 223 dichloride 6darolutamide 5abiraterone 5apalutamide 3olaparib 2niraparib 2cabazitaxel 2atezolizumab 2Pluvicto 2Nivolumab 2zimberelimab 1xentuzumab 1tasquinimod 1sacituzumab govitecan 1sabizabulin 1quemliclustat 1pembrolizumab 1ipatasertib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1TVB-2640 1Standard of Care 1Rosuvastatin Calcium 1Radium-223 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × radium Ra 223 dichloride × Clear all
NCT02803437 2025-07-10

Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases

Bayer

Completed
334 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT02398526 2021-11-02

PARABO

Bayer

Completed
363 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT02450812 2021-11-02

URANIS

Bayer

Completed
86 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03563014 2020-05-20

BELFIGO

Bayer

Completed
164 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT02899104 2020-03-31

Navigant

Bayer

Completed
200 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03325127 2018-10-31

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Bayer

Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡